Chemours Company (CC) AI Stock Analysis

• Market Cap: $2.57B
• Dividend Yield: 3.97%
• Average Volume (3M): 3.70M
• Price to Earnings (P/E): 59.3
• Beta (1Y): 1.89
• Revenue Growth: 2.48%
• EPS Growth: -459.90%
• Country: US
• Employees: 6,000
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.58
• Shares Outstanding: 149,698,300
• 10 Day Avg. Volume: 3,365,441
• 30 Day Avg. Volume: 3,703,324
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.19
• Enterprise Value/Revenue: 0.96
• Enterprise Value/Gross Profit: 5.24
• Enterprise Value/Ebitda: 23.74
• 1Y Price Target: $16.75
• Price Target Upside: -1.53% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 51 Neutral
• Price Target: $15.00 ▼(-11.82% Downside)

The overall stock score of 51 reflects significant financial challenges, including high leverage and negative cash flow, which weigh heavily on the score. Positive technical indicators and a strong dividend yield provide some support, but operational disruptions and mixed earnings call sentiment highlight ongoing risks.

Positive Factors

Strategic Agreements

The strategic agreements with SRF Limited enhance Chemours' market reach and innovation capabilities in fluoropolymers, supporting long-term growth in the Indian market.

Opteon Refrigerants Growth

Strong demand for Opteon Refrigerants, driven by regulatory mandates, boosts Chemours' revenue and profitability, indicating a competitive edge in the HVAC market.

Settlement with New Jersey

The settlement resolves significant environmental claims, reducing legal uncertainties and enhancing Chemours' focus on core operations and strategic initiatives.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting Chemours' ability to invest in growth opportunities and weather economic downturns.

Negative Cash Flow

Negative cash flow reflects inefficiencies in operations, which could strain liquidity and hinder Chemours' capacity to fund strategic initiatives and manage debt.

Operational Disruptions

Operational disruptions in the Titanium Technologies segment could impact production efficiency and profitability, posing a risk to Chemours' market position and financial performance.

Chemours Company Business Overview & Revenue Model

Company Description

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Chemours generates revenue primarily through the sale of its core products across its three main segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment is a significant revenue driver, producing titanium dioxide, which is essential for a wide range of applications. The Fluoroproducts segment includes refrigerants and other fluorinated offerings, benefiting from strong demand in the HVAC and automotive markets. The Chemical Solutions segment provides performance chemicals used in various applications, contributing to diversified revenue streams. Key revenue sources also stem from long-term contracts with major customers in various industries and the company's strategic partnerships that enhance its market reach and innovation capabilities. Additionally, Chemours benefits from its investment in sustainable practices and product development, responding to the increasing market demand for environmentally friendly solutions.

Chemours Company Financial Statement Overview

Summary

Chemours Company is facing financial difficulties with declining profitability and high leverage. Despite slight revenue growth, the company struggles with negative net income and cash flow issues. High debt levels pose a risk, and operational efficiency needs improvement.

Income Statement

The income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) revenue growth is slightly positive at 1.33%, but the company is facing profitability challenges with a negative net income of $420 million. Gross profit margins have declined over the years, and the EBIT and EBITDA margins are lower compared to previous periods, indicating reduced operational efficiency.

Balance Sheet

The balance sheet reveals significant leverage with a high debt-to-equity ratio of 7.57 in the TTM period, indicating potential financial risk. Stockholders' equity has decreased, and the return on equity has turned negative, reflecting the company's struggle to generate returns for shareholders. The equity ratio is also low, suggesting a heavy reliance on debt financing.

Cash Flow

Cash flow analysis indicates challenges in cash generation. The TTM free cash flow is negative, and the free cash flow growth rate has significantly declined. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash. However, the free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.88B	5.78B	6.03B	6.79B	6.34B	4.97B
Gross Profit	1.07B	1.15B	1.31B	1.62B	1.38B	1.07B
EBITDA	237.00M	692.00M	197.00M	1.20B	1.21B	767.00M
Net Income	-420.00M	86.00M	-238.00M	578.00M	608.00M	219.00M
Balance Sheet
Total Assets	7.49B	7.51B	8.25B	7.64B	7.55B	7.08B
Cash, Cash Equivalents and Short-Term Investments	502.00M	713.00M	1.20B	1.10B	1.45B	1.10B
Total Debt	244.00M	4.36B	4.30B	3.81B	3.93B	4.28B
Total Liabilities	7.25B	6.91B	7.51B	6.53B	6.47B	6.27B
Stockholders Equity	237.00M	604.00M	737.00M	1.11B	1.08B	813.00M
Cash Flow
Free Cash Flow	-35.00M	-993.00M	186.00M	447.00M	543.00M	540.00M
Operating Cash Flow	277.00M	-633.00M	556.00M	754.00M	820.00M	807.00M
Investing Cash Flow	-310.00M	-353.00M	-229.00M	-284.00M	220.00M	-234.00M
Financing Cash Flow	-26.00M	-36.00M	172.00M	-685.00M	-560.00M	-449.00M

Chemours Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Positive. The current price of 17.01 is above the 20-day moving average (MA) of 16.06, above the 50-day MA of 14.44, and above the 200-day MA of 14.32, indicating a bullish trend. The MACD of 0.87 indicates Negative momentum. The RSI at 63.76 is Neutral, neither overbought nor oversold. The STOCH value of 65.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CC.

Chemours Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KWR	70 Neutral	2.42B	-308.08	-0.53%	1.40%	-3.09%	-106.46%
IOSP	63 Neutral	1.98B	108.87	1.49%	2.05%	-5.45%	-87.13%
NGVT	61 Neutral	2.05B	-9.46	-179.45%	―	-14.45%	49.92%
OLN	55 Neutral	2.77B	-199.42	-0.73%	3.31%	1.49%	-105.20%
CC	51 Neutral	$2.57B	59.33	-87.50%	3.97%	2.48%	-459.90%
ASH	46 Neutral	2.27B	-2.67	-45.53%	3.30%	-11.38%	-690.99%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Chemours Company Corporate Events

Chemours Appoints New Chair and Lead Director

On September 2, 2025, Chemours Company announced changes in its Board of Directors, appointing Mary Cranston as Chair and Alister Cowan as Lead Independent Director, following Dawn Farrell’s departure to join the Canadian government. These leadership changes are significant for the company’s governance and may influence its strategic direction and stakeholder relations.

Chemours Chair Dawn Farrell Resigns for New Role

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors at The Chemours Company, announced her resignation effective September 2, 2025, to take on a new role as Chief Executive Officer of the Major Projects Office under the Canadian government. The company has yet to decide on her successor, signaling a forthcoming announcement regarding the new Chair of the Board.

Chemours Agrees to $875M Settlement with New Jersey

On August 3, 2025, Chemours, Corteva, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all pending environmental claims, including PFAS contamination, related to their operating sites and statewide issues. The settlement involves a $875 million payment over 25 years, with Chemours responsible for 50% of the payments. The agreement also includes mechanisms for future remediation funding and establishes a Reserve Fund for financial security. Additionally, Chemours entered into an agreement to sell its rights to $150 million in insurance proceeds related to PFAS claims to DuPont and Corteva.